Disease Landscape and Forecast Insights

Introduction: The crowded U.S. rheumatoid arthritis (RA) market boasts nine different biologics representing five distinct drug classes, including the blockbuster tumor necrosis factor-alpha (…

Introduction: The moderate to severe rheumatoid arthritis (RA) market is crowded; multiple targeted therapies are available, including nine different branded biologics, a biosimilar, and a…

The lucrative EU5 rheumatoid arthritis market is dominated by biologics, including five tumor necrosis factor (TNF)-α inhibitors and four biologics with alternative mechanisms of action. The TNF…

Dermatologists have many years of experience with the tumor necrosis factor-alpha (TNF-α) inhibitors Humira (AbbVie) and Enbrel (Pfizer) as first-line biologics for the treatment of psoriasis…

MARKET OUTLOOK The U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets include the predominantly entrenched TNF-α inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s…

In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S…

The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…

Breast cancer affects thousands of individuals in Brazil and Mexico, and is managed with premium-priced agents, chemotherapy, and hormone therapy. In Mexico, coverage of treatment varies across the…

Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…

The success of biologics will greatly depend on payers because they are the ones who determine which products gain formulary access and preferential reimbursement. Understanding the factors that…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United…